The effects of growth hormonereleasing factor (GHRF) injections to sows during late gestation were investigated in two experiments. In the first one, four treatments were applied to eight catheterized sows according to two 4 x 4 Latin squares: oral administration of 2 mg of pyridostigmine, a cholinesterase inhibitor, per kilogram of BW (PYR group); i.m. injection of 50 pg of GHRF/kg BW (GHRF group); a combination of the pyridostigmine and GHRF treatments (PYR + GHRF); or i.m injection of glucose (control).
Introduction
Fetal growth is dependent on the hormonal status of the dam. Chronic administration of GHRF to pregnant ewes for 10 d before parturition increased birth weight and postnatal growth rate of young lambs (Kann et al., 19891. Human growth hormone-releasing factor (GHRF) is a potent stimulator of growth hormone (GH) release in growing pigs (Etherton et al., 1986; Dubreuil et al., 1988) and in gestating or lactating sows Farmer et al., 19911. The human (h) GHRF (1-29)NH2 fragment has the same first 29 aminoacid sequence as the porcine (PI GHRF (1-44)NH2 molecule (Biihlen et al., 1983) with full biological activity on GH release in vitro (Spiess et al., 1982) and the same potency in vivo (Della-Fera et al., 1986;  Petitclerc et al., 1987) .
The cholinergic system positively modulates GH release (Bruni and Meites, 1978; Casanueva et al., 1983) by inhibiting somatostatin (Ross et al., 1987) .
The cholinesterase inhibitor pyridostigmine has been shown to promote both basal and GHRFinduced GH secretion in humans (Massara et al., 1986;  Ghigo et al., 19871. The aim of this study was to determine the effectiveness of hGHRF (1-29)NH2 to stimulate GH secretion in sows during late gestation and to investigate the possible effects on reproductive traits and performance of progeny from birth to 100 kg live weight. A preliminary experiment was conducted to evaluate the effect of GHRF treatment on plasma GH concentrations and to investigate the possible potentiation of GH response to GHRF by pyridostigmine.
Materials and Methods
In Exp. 1, plasma GH profiles were described and GH response to GHRF and(or1 pyridostigmine was measured in sows during late gestation. In Exp. 2, the effects of GHRF treatment of sows during late gestation on reproductive traits and performance of progeny were investigated.
Experiment 1
Animals and Experimental Design. Ten pregnant Large White sows (from 91 to 98 d of gestation at the start of the experiment) of mean parity 2.4 were used. A catheter was inserted into the jugular vein of each animal under general anesthesia 3 or 4 d before the beginning of the experiment. Catheters were kept patent with heparinized saline.
Four treatments were applied consecutively to each animal, at 2-or 3-d intervals, according to a 4 x 4 Latin square design, replicated twice. From the 10 sows that were catheterized, eight were Sampled, and the two others were kept for replacement of animals with failing catheters. Blood samples were first drawn every 20 rnin for 6 h (from 1000 to 1600) 1 d before the application of each treatment. On the day of treatment, animals were treated as follows: 1) pyridostigmine (PYRI-treated animals were given PYR orally (2 mg/kg BWI at time -180 min (0700) and received i.m. isotonic glucose a t time 0 (10001, 21 GHRF-treated animals received a n i.m. injection of GHRF (50 pg/kg BWI in isotonic glucose at time 0, 31 PYR-and GHRF-treated animals (PYR + GHRF) were given PYR orally (2 mg/kg B W at time -180 min and received an i.m. injection of GHRF (50 pg/kg BWI a t time 0, and 4) control animals received a n i.m. injection of isotonic glucose at time 0. Blood samples were drawn every 20 rnin from 120 to 0 rnin before GHRF injection, at +5, +lo, +15, +20, +30, +40, +50 min, and every 20 rnin from 60 to 240 min after GHRF injection. Blood was kept on ice and centrifuged. Plasma was stored at -2OOC until it was analyzed for GH concentration.
Measurement of Plasma Growth Hormone Concentrations. Plasma GH concentrations were determined by a specific homologous double antibody RIA. Antiserum (UCB Bioproducts, Brussels, Belgium) was used at a final dilution of 1/30,000. The USDA-GH-1-1 (AFP-64001 was a gift from the National Hormone and Pituitary Program (University of Maryland School of Medicine) and the National Institute of Diabetes and Digestive and Kidney Diseases. Sensitivity was 1 ng/mL. Crossreactions with porcine prolactin, porcine LH, and porcine FSH were < .4%. Intraassay CV were 9.2, 5.9, and 8.6% for plasma samples containing 3.8, 12.0, and 25.0 ng/mL, respectively. All samples were measured within a single assay.
Data Analysis. Growth hormone secretory profiles in the absence of GHRF treatment were analyzed according to the procedure described by Merriam and Wachter (19821. For each 6-h profile, mean GH and baseline concentrations as well as number and duration of GH pulses were determined. Amplitude of a given GH pulse was defined as the highest GH concentration observed within the pulse.
The GH response to PYR and(or1 GHRF treatment was analyzed by calculating maximum GH concentration and area under the GH curve after GHRF injection. Area under the GH curve was defined as the area included between the GH curve and mean concentrations measured before GHRF injection.
Data were analyzed by analysis of variance, using the GLM procedure of SAS (1988) . For the analysis of plasma GH profiles on the day before treatments, the model included the main effects of previous treatment (to check any residual effect of treatment applied 2 or 3 d before) and animal. For the analysis of PYR effect on plasma GH concentrations (in the absence of GHRF treatment), the model included the main effects of PYR, period, and animal as well as the interaction between PYR and period. For the analysis of maximum GH concentration and area under the GH curve after GHRF injection, the model included the main effects of PYR, GHRF, and animal as well as the interaction between PYR and GHRF. In addition, time was included in the model used for the analysis of GH concentrations after GHRF injection, using the repeated statement of the GLM procedure. When applicable, Tukey's test was used for multiple comparison of the means. Measurements. Sows were weighed at mating, before and after farrowing, and a t weaning. Feed refusals during lactation were weighed. Pigs were weighed individually at birth and at 1, 13, and 22 d of age. Depending on litter size, one or two pigs in each litter were killed by asphyxiation with chloroform at weaning for analyzing their body proximate composition. After the digestive tract was emptied and placed back into the abdomen, the pigs were frozen. After mincing and homogenization, representative samples were freeze-dried and analyzed for DM, N (macro-Kjeldahl), fat (Bligh and Dyer, 19591, and energy (adiabatic bomb calorimetry). Body composition a t weaning of the other pigs was estimated from the proximate composition of killed littermates according to the method described by Noblet and Etienne (1987) . Nitrogen and energy outputs in milk were estimated for each sow from growth rate and body composition of its pigs at weaning, using the equations obtained by Noblet and Etienne (1989) .
The remaining pigs were kept in a postweaning facility and had ad libitum access to feed until 24 kg live weight. At 24 kg live weight, six pigs per litter (three castrated males and three gilts) were moved into a growing-finishing facility (four pigs per pen of the same sex and treatment group) and group-fed to appetite a diet formulated to contain 3.1 Mcal of DE/kg, 17.6% CP, and .85% lysine. Feed intake was recorded for each pen. Pigs were slaughtered at 100 kg live weight. The carcasses of four pigs from each litter (two castrated males and two gilts) were cut and the weight of individual cuts was recorded.
Datu Analysis. Data were analyzed by analysis of variance, using the GLM procedure of SAS (1988) . For reproductive traits, the model included treatment and parity as main effects and the interaction between treatment and parity. Data concerning performance of the pigs before weaning and body composition of the pigs slaughtered at weaning were analyzed according to a split-plot design with treatment as main plot and litter origin as subplot. Estimated daily nutrient intake by the suckled pigs and daily output of milk nutrients were compared with treatment of the dam as sole effect. Growth performance results after weaning were split into two subperiods: growing period from 24 to 60 kg and finishing period from 60 to 100 kg. These data (except for feed intake and feed conversion ratio) were analyzed according to a split-plot design with treatment, sex, and the interaction treatment x sex as main plots and litter origin as a subplot. The model used for feed intake and gain to feed ratio included the main effects of GHRF treatment of the dam, sex, as well as the interaction between sex and treatment.
Results

Experiment 1
Mean GH concentrations measured during a 6-h period, 1 d before the application of treatments, were very low (1.4 ng/mL; Table 11 . Few GH pulses were detected (1.6 per 6 h) and their amplitude was small (2.4 ng/mL). Mean GH and baseline concentrations as well as amplitude of GH pulses were significantly different among Mean plasma GH profiles between 120 min before and 240 min after GHRF or isotonic glucose injection are reported in Figure 1 . In control animals, plasma GH concentrations were low and similar to those measured 1 d before the application of treatments. In PYR-treated sows, plasma GH concentrations were slightly higher (P c .01) than in control sows from time -120 to time 120, sows. *** aMeans f SEM (n = 27, 6-h periods, corresponding to 10 animals). Plasma GH concentrations were measured every 20 min for 6 h on the day before the application of GHRF and(or) pyridostigmine treatments (see Materials and Methods section). There was no significant effect of previously applied treatment.
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corresponding to 60 to 300 min after pyridostigmine administration (Table 2) .
The variation among animals in GH response to GHRF was large. Sows exhibited either immediate (Figure 2a ; three GHRF and two PYR + GHRF sows), delayed (Figure 2b ; two GHRF and three PYR + GHRF sows), or both immediate and delayed (Figure 2c ; three GHRF and three PYR + GHRF sows) response to GHRF injection. The GHRF had a significant effect on plasma GH concentrations from 5 to 240 min after it was injected (Figure 11 . Maximum GH concentrations and area under the GH curve after GHRF injection were significantly higher in GHRF-treated than in control animals ( Table 3 ). The GHRF and PYR + GHRF animals responded similarly to GHRF administration, as demonstrated by the nonsignificant interaction between pyridostigmine and GHRF effects.
Experiment 2
One sow in the control group died just after farrowing and data were collected from the 35 remaining sows. The GHRF treatment increased (P e .05) pregnancy duration by approximately 1 d. The number of pigs born, born alive, and stillborn per litter and pig mean weight at birth were not affected (Table 4) . Sow weight loss during lactation tended to increase in the GHRF group. No feed refusal was recorded during pregnancy and mean feed intake of sows during lactation was similar in the two groups (mean 5.06 kg/d). Pig survival at weaning was higher in the GHRF than in the control group (Table 41 . Sow weight at mating and weight variations during the reproductive cycle were affected by the parity number.
For all traits concerning pig growth before weaning and body composition at weaning, the litter effect was significant ( P < .001). Pig weights a t birth and at 1 d were not affected by GHRF treatment (Table 51 . However, pigs in the GHRF " I group were significantly heavier at 13 d and at weaning at 22 d; the difference from the control pigs amounted to .15 and .26 kg at the two ages, respectively. Dry matter and protein content of the pigs a t weaning did not differ between the two treatments, but lipid and energy contents were higher in the GHRF group. Estimated daily N intake per pig and N output in the milk per sow were similar in the two groups. Pig energy intake was higher in the GHRF group, although the difference was not significant (P = .12). Average daily gain and feed intake of the pigs between 24 and 100 kg were similar in the two treatment groups, and gain:feed ratio was significantly higher in the GHRF group than in the control group (Table 6) . Sex significantly affected almost all these traits during the different growth periods, whereas no significant treatment x sex interaction was observed. Feed intake and ADG were higher for barrows than for gilts during the growing and finishing periods, whereas feed efficiency was lower for barrows than for gilts during the finishing period only.
No effect of GHRF treatment of the dam was noticed on carcass weight and length or on weight of the different carcass cuts ( Table 7) . Gilts at 100 kg live weight had longer carcasses, heavier lean cuts (loin and ham), less fat (backfat and kidney fat), and, as a consequence, a greater 1oin:backfat ratio than did barrows. No significant treatment x sex interaction was observed.
Discussion
The observation that plasma GH concentrations were very low in sows during late gestation, with infrequent, small-amplitude pulses is consistent with previous findings (DeHoff et al., 1986; Esbenshade et al., 1988) . Growth hormone-releasing factor stimulated GH secretion in sows during late gestation, in accordance with recent results (Farmer et al., 19911, as in late-pregnant ewes and beef heifers (Blanchard et al., 1991; Simpson et al., 1991) . However, the response varied extensively according to animals, as previously observed in growing pigs (Della-Fera et al., 1986; Etherton et al., 1986; Petitclerc et al., 1987; Dubreuil et al., 19881. It is generally believed that the delayed (or absent) GH response to GHRF in some pigs is due to elevated secretion of somatostatin tone at the time of GHRF injection.
The cholinesterase inhibitor PYR had a limited, but significant, effect on basal GH secretion during the first 5 h after administration. Therefore, it seems likely that somatostatin concentration was somewhat decreased by the time of GHRF injection (3 h after pyridostigmine administration). However, GH response to GHRF was not higher in sows previously treated with PYR.
To our knowledge, this experiment was the first attempt to investigate the effect of GHRF treatment of pregnant sows on reproductive traits and performance of the progeny. The GHRF treatment increased the duration of pregnancy. Such an effect could not be evident in previous experiments with GH treatments of sows during late gestation (Boyd et al., 1983 ; Spence et al., 1984;  Kveragas et al., 1986) because farrowing was induced by 6.80g
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injecting prostaglandins before the normal term. The GHRF treatment had no effect on litter performance at birth, as observed with GH administration during the last 3 wk of gestation (Kveragas et al., 1986). Kann et al. (1988) showed that GHRF treatment during the mammogenesis period of pregnancy increased milk production in ewes. Such a n effect seems less clear in the sow because in the present experiment, N and energy output in milk over the whole lactation were not significantly higher in the GHRF sows. This is consistent with previous data demonstrating that milk production was not affected in sows administered GH during gestation (Kveragas et al., 1986) . However, pigs born from GHRF-treated sows were fatter at weaning, suggesting that milk fat content was increased. This assumption is supported by the tendency for higher weight loss during lactation in the GHRF sows despite a similar feed intake. Somatotropin treatment of sows during gestation and lactation has been found to increase lipid content of colostrum (Boyd et al., 1983; Spence et al., 19841 and milk at 13 d of lactation (Boyd et al., 1983) . However, previous observations have shown that milk composition is not affected in sows treated with GH during pregnancy only (Kveragas et al., 1986) or lactation only (Harkins et al., 19891 or in sows administered GHRF during lactation (Dubreuil et al., 1990) .
The tendency for a greater milk energy intake by the pigs in the GHRF group may account for their higher survival rate, although other possible explanations can be invoked. First, pigs born from GHRF-treated sows were approximately 1 d older at birth and may have been more mature and more active. Second, the GHRF treatment itself Kveragas et al., 1986) and total lipid content of could improve pig maturity. Indeed, GH treatment newborn pigs (Kveragas et al., 1986 ). This could be of sows during late pregnancy has been shown to related to the induction of diabetogenic state in increase concentration of glycogen in liver and the sows (Kveragas et al., 1986) . Moreover, Boyd et carcass (Boyd et al., 1983;  Spence et al., 1984;  al. (1986) showed that pigs from GH-treated sows maintained a higher blood glucose concentration than did pigs from control sows when fasted during 24 h. Glycogen and lipid contents of the pigs a t birth were not determined in the present experiment. However, it seems likely that their energy reserves were improved because the first experiment demonstrated that GHRF injections increased GH release in sows. Whatever the reason, this is the first experiment showing an improved postnatal survival of pigs in sows with enhanced plasma GH concentrations, an effect that was suggested as possible by Kveragas et al.
(1986).
Higher milk energy intake by the pigs in the GHRF group may explain why they were approximately 5% heavier at weaning, a difference similar to that reported by Harkins et al. (1989) in pigs from sows treated with GH during the second part of lactation. The effect of GHRF treatment on pig growth was, however, limited to the lactation period because performance after weaning was similar in the two groups: the pigs reached slaughter weight at a similar age and their body composition was comparable. Gain:feed ratio was significantly, although slightly (3901, improved in the GHRF group. In the absence of any significant difference on other performance traits, the reasons for this effect are unclear.
Implications
The present data support the hypothesis that stimulation of growth hormone secretion in sows obtained through twice-daily injections of growth hormone-releasing factor during the last 2 wk of pregnancy may improve pig survival during the following lactation and increase pig weight at weaning. Growth rate after weaning and body composition at 100 kg live weight are not affected, although feed efficiency is slightly improved in pigs born from dams treated with growth hormone-releasing factor.
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